Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilege

doi:10.3748/wjg.v11.i23.3632

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2858)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

246

HTML

2334

Figures (1-3)

159

Tables (1-1)

119

Sum=2858

Jun 21, 2005 (publication date) through May 19, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Jun 21, 2005; 11(23): 3632-3635
Published online Jun 21, 2005. doi: 10.3748/wjg.v11.i23.3632

Open in New Tab Full Size Figure Download Figure

Figure 1 Expression of FasL in normal colon mucosae (A) and colon cancer (B).

Open in New Tab Full Size Figure Download Figure

Figure 2 Western blotting result of the expression of FasL in colon cancer cell lines. Lane 1: SW620; lane 2: SW1116; lane 3: LS-174T; lane 4: Lovo.

Open in New Tab Full Size Figure Download Figure

Figure 3 Apoptosis of Jurkat cells (A) and apoptosis of Jurkat cells after being cocultured with SW1116 cells (B).

Citation: Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL, Wang YH. Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilege. World J Gastroenterol 2005; 11(23): 3632-3635
URL: https://www.wjgnet.com/1007-9327/full/v11/i23/3632.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i23.3632